PTAB Knocks Out Two Copaxone 40 mg Patents

Patent Trial and Appeal Board finds claims in '250 and '413 patents covering 40 mg dosage are unpatentable, giving generic manufacturers a chance at early entry once FDA approves ANDAs.

Teva Pharmaceutical Industries Ltd. could face earlier competition for its 40 mg/mL three-times-a-week dosage of Copaxone (glatiramer) now that the US Patent and Trademark Office's Patent Trial and Appeal Board has determined that two patents covering the product are not patentable.

On Aug. 24, PTAB issued a pair of final written decisions on inter partes review petitions challenging the patents on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet